Innate Pharma (IPHYF) Retained Earnings (2017 - 2025)
Innate Pharma's Retained Earnings history spans 9 years, with the latest figure at -$57.2 million for Q4 2025.
- For Q4 2025, Retained Earnings rose 84.1% year-over-year to -$57.2 million; the TTM value through Dec 2025 reached -$57.2 million, up 84.1%, while the annual FY2025 figure was -$57.2 million, 84.3% up from the prior year.
- Retained Earnings reached -$57.2 million in Q4 2025 per IPHYF's latest filing, up from -$360.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $835582.6 in Q4 2022 to a low of -$360.0 million in Q4 2024.
- Average Retained Earnings over 5 years is -$84.8 million, with a median of -$8.1 million recorded in 2023.
- Peak YoY movement for Retained Earnings: plummeted 4319.99% in 2024, then soared 84.1% in 2025.
- A 5-year view of Retained Earnings shows it stood at $521650.8 in 2021, then surged by 60.18% to $835582.6 in 2022, then tumbled by 1074.75% to -$8.1 million in 2023, then tumbled by 4319.99% to -$360.0 million in 2024, then skyrocketed by 84.1% to -$57.2 million in 2025.
- Per Business Quant, the three most recent readings for IPHYF's Retained Earnings are -$57.2 million (Q4 2025), -$360.0 million (Q4 2024), and -$8.1 million (Q4 2023).